IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0587619
(2012-08-16)
|
등록번호 |
US-8658177
(2014-02-25)
|
발명자
/ 주소 |
- Wollan, Jami B.
- Jones, Lori A.
|
출원인 / 주소 |
|
대리인 / 주소 |
Kilpatrick Townsend & Stockton LLP
|
인용정보 |
피인용 횟수 :
0 인용 특허 :
2 |
초록
▼
The present invention relates to the discovery of novel T cell epitopes of the human HER-2/Neu protein that is promiscuous for at least 25 different HLA-DR alleles. The invention also relates to compositions that contain one of the novel epitopes or a fusion peptide of such a epitope and a heterolog
The present invention relates to the discovery of novel T cell epitopes of the human HER-2/Neu protein that is promiscuous for at least 25 different HLA-DR alleles. The invention also relates to compositions that contain one of the novel epitopes or a fusion peptide of such a epitope and a heterologous polypeptide. Further disclosed herein is the use of the epitopes or their fusion peptides, and compositions containing the epitopes or their fusion peptides.
대표청구항
▼
1. A method for inducing in a patient a T cell immune response specific to a HER-2/Neu protein, the method comprising the step of administering an effective amount of a composition comprising a peptide consisting of the amino acid sequence of SEQ ID NO: 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or
1. A method for inducing in a patient a T cell immune response specific to a HER-2/Neu protein, the method comprising the step of administering an effective amount of a composition comprising a peptide consisting of the amino acid sequence of SEQ ID NO: 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 31 to the patient. 2. The method of claim 1, wherein the composition comprises a fusion protein comprising the peptide and a heterologous polypeptide. 3. The method of claim 2, wherein the peptide is fused to the heterologous polypeptide via a peptide bond. 4. The method of claim, wherein the heterologous polypeptide is a granulocyte-macrophage colony-stimulating factor (GM-CSF). 5. The method of claim 2, wherein the peptide has the amino acid sequence of SEQ ID NO:2. 6. The method of claim 1, wherein the composition comprises a physiologically acceptable excipient. 7. The method of claim 1, wherein the peptide is selected from the group consisting of: SEQ ID NOs: 20, 21, 22, or 23. 8. The method of claim 1, wherein the peptide is selected from the group consisting of: SEQ ID NOs: 24, 25, or 26. 9. The method of claim 1, wherein the peptide is selected from the group consisting of: SEQ ID NOs: 27, 28, 29, or 31. 10. The method of claim 1, wherein the peptide has the amino acid sequence of SEQ ID NO:2.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.